Pleiotropic effects and cholesterol-lowering therapy. - Wikidata - awgldk - TriplyDB

Pleiotropic effects and cholesterol-lowering therapy.

Pleiotropic effects and cholesterol-lowering therapy.

http://www.wikidata.org/entity/Q37199617

about

Inhibiting geranylgeranylation increases neurite branching and differentially activates cofilin in cell bodies and growth cones Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation Renal lipid metabolism and lipotoxicity.Pleiotropic vasoprotective effects of statins: the chicken or the egg?Advancing therapy for hypercholesterolemia.Statins and pregnancy: between supposed risks and theoretical benefits.The role of the host defense system in the development of cerebral vasospasm: analogies between atherosclerosis and subarachnoid hemorrhage.The good and bad effects of statins on insulin sensitivity and secretion.Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.Genetic basis for developmental toxicity due to statin intake using embryonic stem cell differentiation model.The self-limiting nature of statin-induced rhabdomyolysis.Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis.Different responses of fluvastatin to cholesterol-induced oxidative modifications in rabbits: evidence for preventive effect against DNA damage.Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry.

P2860

Q28569470-8E105BA6-F86E-40AF-83D9-4BFB8A194AE8 Q28729147-AA1AEEBB-35CE-40CE-A28D-E19E4C9879C0 Q34562390-D66782EE-D223-4360-A322-BB5818269E2B Q34825296-E1FBAF4B-FC8F-4289-A8FA-B3BA238CD6AF Q37403235-E48835B2-3F83-47F4-A883-3C45C024F039 Q37761373-895A7F21-5725-4594-B3D8-212FE9EC1C61 Q38000338-28C59492-98C2-41EC-A660-632139EE1CAD Q38055310-6409871A-22D6-480B-9561-E97DF05E5ABB Q38248109-659DCD98-550A-447C-85D7-99D9C5BB99A8 Q38832643-2FD78E40-A7E3-4F1F-BC1E-21FAF91A246D Q38906383-FA62AB37-A83A-4AFD-9393-6EC15A47009D Q42204450-99D86520-C2A7-4024-B790-C175EB7FFDBE Q42822193-074A0084-6A98-4C67-9BF8-6FCBE581617E Q43905418-6138C6CC-048C-4501-96B6-4E654556B779 Q44548364-E3270721-4778-41F4-94AB-694FFD3405A6 Q47286408-8D98CB21-EC01-4889-980B-0D414313C941

P2860

Pleiotropic effects and cholesterol-lowering therapy.

http://www.wikidata.org/entity/Q37199617

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pleiotropic effects and cholesterol-lowering therapy.

@en

Pleiotropic effects and cholesterol-lowering therapy.

@nl

type

label

Pleiotropic effects and cholesterol-lowering therapy.

@en

Pleiotropic effects and cholesterol-lowering therapy.

@nl

prefLabel

Pleiotropic effects and cholesterol-lowering therapy.

@en

Pleiotropic effects and cholesterol-lowering therapy.

@nl

P1433

Q37199617-3CD6E55D-8412-4A25-9740-9A2D94A6CD54

P1476

Q37199617-1599A296-8FED-4E99-95E3-7C36C8BF93A4

P2093

Q37199617-8518058F-2418-4DAC-AAB8-55E7F6CF10EE

Q37199617-A94D094F-9868-4A23-8AFB-9F881E57A08F

Q37199617-AB3FB1B2-9976-4A6C-88F3-FC2C8E9EDEEA

P2860

Q37199617-087D2C39-B435-44CF-BA49-C8BB8180D116

Q37199617-1663C4A9-C60A-4730-AAA5-68F4AF44C75E

Q37199617-1E67E6AB-DD55-4608-BA15-66046FCD2A60

Q37199617-2A9BA523-0AD6-4378-9BFA-19C133B585BE

Q37199617-338FB11C-BE52-4E42-B103-37CF11F39037

Q37199617-37F2D861-1AEF-4B90-B90C-4EB02433755F

Q37199617-3F0535A6-7F0A-4B97-938A-1DFC85BC1E32

Q37199617-7100DDC2-0580-4395-902F-F279EFE7EF7D

Q37199617-9634CF48-6BAE-4F19-B503-E5B9F52FDCEC

Q37199617-B22EE1C3-C52A-4C8A-BCDC-142F6CFFDD7F

P304

Q37199617-03A8CD46-3D98-43A4-A36B-3064FF426960

P31

Q37199617-B92F4908-93DD-463C-B586-0D2EE5848554

P356

Q37199617-DF38599C-C1D2-4D2D-B5ED-A84B6883E90F

P407

Q37199617-33F1340A-EB4A-4C72-A1C0-C0F51D73F5D8

P433

Q37199617-FD493E0A-60DC-48F6-9D78-ED945CFBF393

P478

Q37199617-A6A687EC-C109-48BE-BD12-7066CFCE2755

P50

Q37199617-38C9A5D7-74DC-4825-B59C-E927DCFDF126

P577

Q37199617-8486D74B-3D34-41E9-97B5-FF548C9E4712

P698

Q37199617-1EBE419F-CF2C-4AD7-922F-1A1B5B003F54

P356

P1433

P1476

Pleiotropic effects and cholesterol-lowering therapy

@en

P2093

Nizar Yonan

http://www.w3.org/2001/XMLSchema#string

Simon G Williams

http://www.w3.org/2001/XMLSchema#string

Steven M Shaw

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

C-reactive protein (CRP)-lowering agents

Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase

Drug treatment of lipid disorders.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials.

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

P304

4-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000137692

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18577880

http://www.w3.org/2001/XMLSchema#string